Correction: Effectiveness of plasma lyso-Gb3 as a biomarker for selecting high-risk patients with Fabry disease from multispecialty clinics for genetic analysis (Genetics in Medicine, (2019), 21, 1, (44-52), 10.1038/gim.2018.31)

Hiroki Maruyama; Kaori Miyata; Mariko Mikame; Atsumi Taguchi; Chu Guili; Masaru Shimura; Kei Murayama; Takeshi Inoue; Saori Yamamoto; Koichiro Sugimura; Hiroshi Satoh; Satoshi Ishii

doi:10.1038/S41436-018-0125-2

Cited By1

Newest

Clinical characteristics of patients with alpha-galactosidase A gene variants in a German multicentre cohort of early undifferentiated arthritis

Sep 1, 2019·Annals of the Rheumatic Diseases19.10

#1Stefan Vordenbäumen (HHU: University of Düsseldorf)H-Index: 14

#2Ralph Brinks (HHU: University of Düsseldorf)H-Index: 20

Last. Matthias Schneider (HHU: University of Düsseldorf)H-Index: 71

view all 5 authors...

Fabry disease (FD) is a rare lysosomal storage disorder caused by mutations of the alpha-galactosidase A gene ( GLA ) which causes premature morbidity due to organ dysfunction following deposition of globotriaosylceramide (Gb3).1 Presenting symptoms include musculoskeletal pain such as acroparesthesias2 which often result in rheumatological consultations.3 Concerns have been raised that patients with FD are often falsely attributed with classical rheumatological diagnoses, precluding early effec...more

Source